MedDataX Logo

Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

NCT ID: NCT03366688

Last Updated: 2020-12-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

58 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-27

Study Completion Date

2018-11-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol（LDL-C）uptake. This is a randomized, double-blind, placebo-controlled,single ascending dose study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and immunogenicity of IBI306 in healthy adults.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ascending dose design includes 6 dose levels （25 mg, 75 mg, 150 mg, 300 mg, 450 mg and 600 mg). Tolerance and safety data up to 14 days after dosing from all subjects of the previous cohort will be reviewed before proceeding to the next dose. Total duration of the study per subject is 12 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypercholesterolemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IBI306

Subcutaneous or intravenous injection of a single dose of IBI306, dose level according to ascending dose design

Group Type ACTIVE_COMPARATOR

IBI306

Intervention Type DRUG

Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.

placebo

Subcutaneous or intravenous injection of a single dose of placebo, dose level according to ascending dose design

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IBI306

Cohort 1: 25 mg Subcutaneous(SC) (this cohort is open label without placebo); Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.

Intervention Type DRUG

placebo

Cohort 2: 75 mg SC; Cohort 3: 150 mg SC; Cohort 4: 75 mg IV; Cohort 5: 300 mg SC; Cohort 6: 450 mg SC; Cohort 7: 600 mg SC; Cohort 8: 450 mg IV.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chinese healthy men or women aged 18 to 55 years old at screening (inclusive）;
* Serum LDL-C concentration between 1.8 mmol/L and 4.9 mmol/L (inclusive）at screening;
* Body mass index between 19 and 28 kg/m2 (inclusive);
* Willing to maintain the current regular diet and physical activity;
* Female subjects and male subject's partner who could become pregnant should take effective contraceptions during the treatment period and 6 months after dosing;
* Without any medical history of serious diseases;
* Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent.

Exclusion Criteria

* Breast-feeding or pregnant women;
* History of allergic reaction;
* Previously received any anti-PCSK-9 treatment;
* Vital signs, physical examination, clinical laboratory test, 12-lead ECG, and chest X-ray are abnormal with clinical significance;
* Not willing to stop intense physical activities (such as weight lifting or long-distance running) before 72 hours of the scheduled visits;
* Any hospitalization within one month before screening, or major surgery within six months before screening, or any other unstable medical condition;
* Received an investigational chemical agent within 30 days before dosing；
* Received an investigational biological agent within 90 days before dosing；
* Use of medications including over-the-counter medication within 14 days or less than 5 half-lifes of the agent;
* Use of herb,vitamins or nutraceutical in order to alter serum lipids;
* Positive screen of hepatitis B surface antigen, hepatitis C virus, human immunodeficiency virus or syphilis infection at screening；
* History or clinical evidence of alcohol or drugs of abuse within 12 months before screening;
* With any consumption of alcohol and caffeinated beverages within 72 hours prior to and during the trial;
* Blood donations or blood loss 200 ml and more within 2 months before screening;
* History of organ transplantation or malignant tumor;
* Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment.
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peking University First Hospital

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIBI306A101

Identifier Type: -

Identifier Source: org_study_id